MVP CEO transition: Anita James steps in as interim CEO
Medical Developments International (ASX: MVP) has announced an MVP CEO transition, with Chief Executive Officer Brent MacGregor advising of his intention to step down. Chief Financial Officer Anita James has been appointed interim CEO, effective 15 October 2026.
The Board said the appointment ensures “continuity of strategic momentum”. Mr MacGregor will continue to support the company in an advisory capacity until 15 November 2026 to ensure a smooth transition, and the Board has commenced a search for a permanent CEO.
When big ASX news breaks, our subscribers know first
Leadership handover at a glance
The table below summarises the key points of the handover as stated in the announcement.
| Item | Detail |
|---|---|
| Outgoing CEO | Brent MacGregor, **six years** leading MVP, advisory support until **15 November 2026** |
| Interim CEO | Anita James, Chief Financial Officer, effective **15 October 2026** |
| Remuneration | Ms James’s remuneration remains as stated on **page 38** of the 2026 Annual Report |
| Permanent CEO | Search commenced |
| Investor webcast | **11am, Thursday 15 October** |
The announcement does not give a timeline for the permanent CEO appointment.
Six years of progress under Brent MacGregor
What the Board says was delivered
Chair Mark Fladrich said Mr MacGregor transformed the company into a more efficient and strategically focused business. The achievements listed by the Chair were:
- Grown Penthrox revenues
- Improved margins
- Delivered strong cash generation
- Secured regulatory milestones, including the recent paediatric indication approval in the UK and EU
The announcement does not include financial figures for these achievements. Mr MacGregor referred to the progress illustrated in the company’s recent FY26 results as an indication the company is well advanced on its journey.
Director quotes
The Chair framed the outgoing CEO’s legacy as a platform for future growth.
Mark Fladrich, Chair
“Brent has built a strong foundation for future growth. The business is well-positioned, our strategy is clear, and we have capable leadership in place to execute on the opportunities ahead…”
Mr Fladrich also said the Board fully supports the departure, which is linked to a return to family.
“We fully support Brent’s decision to return home,” he said.
Brent MacGregor, outgoing CEO
“I am returning to North America, where my family is based, confident that the business is in excellent hands…”
Understanding Penthrox and why continuity matters
Penthrox® is the product at the centre of MVP’s growth story, and the company describes it in the following terms:
- A non-opioid trauma and emergency pain relief product manufactured by MVP
- Approved in Australia for pain relief in settings such as hospitals, ambulance services and short procedures, in accordance with the approved Product Information
- Linked by Mr MacGregor to growing Penthrox adoption and securing regulatory approvals that “strengthen the platform for future growth”
For investors, those themes of adoption and regulatory approvals are the ones management has highlighted. Leadership stability during a transition is therefore relevant to how the company continues to pursue them.
Why Anita James is positioned to lead
Mr Fladrich described the interim CEO’s background in the following terms.
Mark Fladrich, Chair
“She brings deep knowledge of our business, a thorough understanding of our financial position and capital allocation priorities, and strong relationships across the organisation and with our external stakeholders…”
The Chair said her appointment “ensures continuity and maintains momentum during this transition period”. The announcement does not outline any change to strategy under the interim arrangement.
As a practical next step for investors, the announcement states that “The Chair and Interim CEO, Anita James, will hold a webcast for investors at 11am, Thursday 15 October”. Registration is via a link provided in the announcement.
What to watch next
Several milestones are relevant for investors following the handover:
- The outcome of the Board’s search for a permanent CEO
- The end of Mr MacGregor’s advisory period on 15 November 2026
- The investor webcast at 11am, Thursday 15 October
The Board’s message is that the strategy is clear and capable leadership is in place to pursue the opportunities ahead.
Don’t Miss the Next Healthcare Leadership Shake-Up
Join 20,000+ investors getting FREE breaking ASX news delivered to their inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to stay ahead of the market on healthcare announcements the moment they break.